Discriminating Value of Calprotectin in Disease Activity and Progression of Nonradiographic Axial Spondyloarthritis and Ankylosing Spondylitis

Table 1

Clinical characteristics and laboratory results in the AS and nr-axSpA patients.

	AS group	nr-axSpA group
Age (mean ± SD, years)	32.3 ± 8.21	34.4 ± 7.79
Disease duration (mean ± SD, years)	5.17 ± 3.55	4.98 ± 4.14
ESR (mm/h)	32.21 ± 16.97	34.58 ± 18.54
CRP (mg/l)	13.75 ± 8.61	13.11 ± 10.16
BASDAI	3.44 ± 1.11	4.20 ± 1.44
BASFI	46.87 ± 17.96	48.78 ± 18.85
ASDAS	1.72 ± 0.97	1.91 ± 0.96
Calprotectin (ng/ml)	15.30 ± 6.49	17.76 ± 8.59
GSK-β (ng/ml)	0.32 ± 0.02	0.53 ± 0.21
β-catenin (ng/ml)	1.69 ± 0.79	1.63 ± 0.65
RUNX2 (ng/ml)	0.28 ± 0.05	0.30 ± 0.07
SPARCC	5.60 ± 5.24	5.88 ± 5.72
mSASSS	18.57 ± 14.72	12.49 ± 11.48